| Research Abstract |
Drug resistance is acquired in the anticamcer drug in leukemia, and it is an important problem to become treatment resistance. Because of that, an anticancer drugresistant acquired is made clear, and the same has the gene which relates to the resistance, and it is necessary to decide early diagnosis. The various quantities to measure it in a small quantity were developed in the leukemia. First, the important factor involved in the acute leukemia cleared that it was deoxycytidine kinase (dCK) involved in a MDR1 gene to be involved in the multidrug resistance and a MRP1 gene, araCresistant. It was confirmed, and cut off value in the clinical inspection with patients, was established the quantitative way of detecting these amounts of genetic expression to establish realtime quantity to be excellent in the sensitivity and the peculiarity in the fundamental examination which it tried. The detection sensitivity of this way was high in comparison with usual multipledrug resistance, and it was shown by that result that it was useful for the diagnosis of anticancer resistant in the clinical target. Specially, relevance with the first treatment resistance and the amount of MDR1 expression with the acute leukemia and the recurrence was suggested, and it was shown that it was useful for the prediction of the treatment resistance in the MDR1 genetic. But, it isn't clear from the examination record until now, and it must pile up an examination more as for the relation between the amount of exprission and the treatment resistance between MRP1 and dCK. Therefore, it was proved that was the clinical way of introducing this way as an early diagnosis of anticancer resistant and of examining it, and clinical target meaning was explained. Furthermore, if it has the gene related to the resistance of every anticancer drug, it can be applied to the genetic quantity by this way, and it is suggested that it is useful for the comparison with the recent DNA array analysis
|
